John R Goffin

John R Goffin

UNVERIFIED PROFILE

Are you John R Goffin?   Register this Author

Register author
John R Goffin

John R Goffin

Publications by authors named "John R Goffin"

Are you John R Goffin?   Register this Author

33Publications

650Reads

38Profile Views

Lung Cancer Screening, Cancer Treatment, and Addressing the Continuum of Health Risks Caused by Tobacco.

Am Soc Clin Oncol Educ Book 2016 ;35:223-9

From the Departments of Radiation Oncology and Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC; Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_158704DOI Listing
January 2017

American Society of Clinical Oncology Policy Brief: FDA's Regulation of Electronic Nicotine Delivery Systems and Tobacco Products.

J Oncol Pract 2017 01 23;13(1):58-60. Epub 2016 Oct 23.

American Society of Clinical Oncology, Alexandria, VA; Medical University of South Carolina, Charleston, SC; McMaster University Juravinski Cancer Centre, Hamilton, Ontario, Canada; Emory University, Winship Cancer Institute, Atlanta, GA; and Moffit Cancer Center, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2016.018200DOI Listing
January 2017

Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.

Lung Cancer 2016 11 28;101:98-103. Epub 2016 Sep 28.

Department of Oncology, McMaster University, 699 Concession St., Hamilton, ON, L8V 5C2, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.09.013DOI Listing
November 2016

Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses--Reply.

JAMA Oncol 2016 Feb;2(2):278-9

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4462DOI Listing
February 2016

Perspective on the National Comprehensive Cancer Network's Clinical Practice Guidelines for Smoking Cessation.

J Oncol Pract 2016 Jan 15;12(1):55-8. Epub 2015 Sep 15.

Memorial Sloan Kettering Cancer Center, New York, NY; Juravinski Cancer Centre, McMaster University, Hamilton, Canada; American University of Beirut, Beirut, Lebanon; and Hollings Cancer Center, Medical University of South Carolina, Charleston, SC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2015.006148DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979976PMC
January 2016

Cost-effectiveness of Lung Cancer Screening in Canada.

JAMA Oncol 2015 Sep;1(6):807-13

Department of Oncology, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.2472DOI Listing
September 2015

Epidermal growth factor receptor: pathway, therapies, and pipeline.

Clin Ther 2013 Sep;35(9):1282-303

Department of Oncology, Faculty of Health Sciences, McMaster University, Hamilton, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinthera.2013.08.007DOI Listing
September 2013

Do beta-blockers alter dyspnea and fatigue in advanced lung cancer? A retrospective analysis.

Palliat Med 2012 Sep 15;26(6):797-803. Epub 2011 Aug 15.

Queen's University, Faculty of Medicine, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0269216311415454DOI Listing
September 2012

A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.

Invest New Drugs 2012 Jun 28;30(3):1203-7. Epub 2011 Apr 28.

University Health Network-Princess Margaret Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-011-9673-xDOI Listing
June 2012

Stopping rules employing response rates, time to progression, and early progressive disease for phase II oncology trials.

BMC Med Res Methodol 2011 Dec 12;11:164. Epub 2011 Dec 12.

McMaster University, Juravinski Cancer Centre, Hamilton, Ontario L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2288-11-164DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259049PMC
December 2011

Early stopping rules in oncology: considerations for clinicians.

Eur J Cancer 2011 Nov 16;47(16):2381-6. Epub 2011 Jun 16.

Department of Oncology, McMaster University, Juravinski Cancer Centre, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2011.05.019DOI Listing
November 2011

A comparison of a new multinomial stopping rule with stopping rules of fleming and gehan in single arm phase II cancer clinical trials.

BMC Med Res Methodol 2011 Jun 21;11:95. Epub 2011 Jun 21.

McMaster University, Juravinski Cancer Centre, 699 Concession St,, Hamilton, Ontario, L8V 5C2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2288-11-95DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138426PMC
June 2011

Phase II stopping rules that employ response rates and early progression.

J Clin Oncol 2008 Aug;26(22):3715-20

Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.1044DOI Listing
August 2008

Overstated conclusions of a pooled analysis of bevacizumab in colon cancer.

J Clin Oncol 2006 Jan;24(3):528-9; author reply 529-30

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.04.3570DOI Listing
January 2006

DEALE-ing with lung cancer and heart failure.

Med Decis Making 2005 Jan-Feb;25(1):82-94

Department of Medicine, Division of Clinical Desicion Making, Tufts-New England Medical Center, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X05274523DOI Listing
May 2005

Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer.

Am J Clin Oncol 2004 Apr;27(2):172-7

McGill University Health Centre, Montreal General Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000054890.69365.3eDOI Listing
April 2004

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.

Cancer Res 2004 Feb;64(3):830-5

Program in Cancer Genetics and Department of Oncology, Research Institute of the McGill University Health Centre, and Cancer Prevention Centre, Sir M. B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
February 2004

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

J Natl Cancer Inst 2003 Oct;95(19):1482-5

Program in Cancer Genetics, Department of Oncology and Human Genetics, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djg050DOI Listing
October 2003

Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers.

Cancer Res 2002 Dec;62(23):6808-11

Department of Pathology, The Gade Institute, University of Bergen, Bergen 5021, Norway.

View Article

Download full-text PDF

Source
December 2002